Hyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 10, 2013

Primary Completion Date

July 9, 2019

Study Completion Date

July 9, 2019

Conditions
Temporomandibular Joint Disc DisplacementTemporomandibular Joint Disorders
Interventions
BIOLOGICAL

Hyaluronic Acid

1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .

PROCEDURE

Temporomandibular Joint Arthroscopy

Lysis and Lavage

DRUG

Antibiotic therapy

Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).

DRUG

corticosteroid

Dexamethasone, 4 mg I.V. (Intraoperative)

DRUG

Antiinflammatories

Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).

DRUG

Analgesics

Metamizol 575 mg / 8h by mouth (Post-operatively)

OTHER

Exercise program

Home exercise program

Trial Locations (1)

28006

Hospital Universitario de La Princesa, Madrid

All Listed Sponsors
collaborator

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

collaborator

Zambon SpA

INDUSTRY

lead

Universidad Complutense de Madrid

OTHER

NCT04110587 - Hyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy | Biotech Hunter | Biotech Hunter